Cisplatin Injection

This product is a metal complex of platinum, and its action is similar to that of an alkylating agent. Its main target is DNA, and it acts on the cross-links between DNA chains and within the chains to form a DDP-DNA complex, interfering with DNA replication, or binding to nuclear and cytoplasmic proteins. It is a non-specific drug for the cycle.

The main ingredient is cisplatin, and its chemical name is cis-dichlorodiammineplatinum.

This product is a slightly viscous light yellow clear solution.

This product is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

This product needs to be diluted with 300-500ml sodium chloride injection for dripping. This drug is slightly sticky. In order to make the dosage accurate, after sucking out the liquid, inject an appropriate amount of sodium chloride injection into the bottle, shake it slightly to wash the liquid adhering to the inner wall of the bottle, then suck it out and add it to the infusion bottle for dripping. 1 Intravenous drip once according to body surface area 20mg/m2, once a day, for 5 consecutive days; or 30mg/m2, once a day, for 3 consecutive days, repeat after 3 weeks, and repeat 3-4 courses. It can also be 80-100mg/m2, and hydration therapy and diuresis are performed at the same time, and the medication is used once every 3-4 weeks. 2 When combined with arterial perfusion interventional chemotherapy, 40-50mg/m2 each time, once every 4 weeks, hydration and diuresis are required. 3 Thoracic and abdominal injections are 30-60mg each time, once every 7-10 days.

1. Digestive tract reactions: severe nausea and vomiting are the main limiting toxicities. Acute vomiting generally occurs 1 to 2 hours after administration and can last for about a week. Therefore, when using this product, it is necessary to use a strong antiemetic, such as the 5-hydroxytryptamine 3 (5-HT3) receptor antagonist antiemetic ondansetron, which can basically control acute vomiting; 2. Renal toxicity: cumulative and dose-related poor renal function is the main limiting toxicity of cisplatin. Generally, a daily dose exceeding 90 mg/m2 is a risk factor for renal toxicity. It is mainly renal tubular damage. Acute damage is generally seen 10 to 15 days after medication, with increased blood urea nitrogen (BUN) and creatinine (Cr), decreased creatinine clearance, and most of them are reversible. Repeated high-dose treatment can cause persistent mild to moderate renal damage. At present, there is no effective means to prevent renal toxicity caused by this product except hydration; 3. Neurotoxicity: Neurological damage such as tinnitus and hearing loss caused by auditory nerve damage are more common. Peripheral neurotoxicity is related to the cumulative dose increase, which is manifested as varying degrees of weakened or lost sensation in the hands and feet, sometimes with extremity paralysis, decreased trunk muscle strength, etc., which are generally difficult to recover. Epilepsy and papilledema or retrobulbar neuritis are less common; 4 Bone marrow suppression: Bone marrow suppression (decreased white blood cells and/or platelets) is generally mild, and the probability of occurrence is related to the dose of each course of treatment. If the dose is 100mg/m2, the probability of occurrence is about 10% to 20%, and if the dose is 120mg/m2, it is about 40%, but it is also related to the overlap of bone marrow toxicity of other anticancer drugs in combined chemotherapy; 5 Allergic reactions: facial swelling, asthma, tachycardia, hypotension, and non-specific maculopapular rash may occur; 6 Others: abnormal heart function and liver function changes are rare.

It is contraindicated in patients with renal impairment and pregnant women.

Precautions during pregnancy and lactation: Contraindicated for use during pregnancy.

The combined use of aminoglycoside antibiotics, amphotericin B, etc. with this product has an additive nephrotoxic effect; MTX and BLM are mainly excreted by the kidneys, and the renal damage caused by this product will delay the excretion of the above two drugs, resulting in increased toxicity. When probenecid is used in combination with this product, it can cause hyperuricemia; chloramphenicol or its furosemide or sodium urate increases the ototoxicity of this product; antihistamines can mask the symptoms of tinnitus, dizziness, etc. caused by this product.

Seal and store.

6 ml: 30 mg

Yunnan Biovalley Pharmaceutical Co., Ltd.

• Founded in:

  1999-06-13

• Address:

  No. 1, Kangjian Road, Yunnan Mile Industrial Park, Fucheng Subdistrict Office, Mile City, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province

• Tax NO.:

  915301007134092367

• Registered Funds:

  124.00007 million yuan

• Website:

  Log in to view

• Email:

  Log in to view